BioMed Research International

Review Article

Possible Future Monoclonal Antibody (mAb)-Based Therapy against Arbovirus Infections

Table 1

Schematic summary of the best characterized mAbs against arboviral pathogens.


mAb	Origin	Reactivity	Target protein	Epitope	Cloning strategy	Format/isotype	Neutralizing activity	Reference

4.8A	Human	DENV1–4	E	DII	EBV transformation	IgG	IC50 (μg/mL): DENV1: 1.5 DENV2: >40 DENV3: 2.4 DENV4: >40	[37]
D11C							IC50 (μg/mL): DENV1: 1.5 DENV2: 1.0 DENV3: 10.2 DENV4: 1.6
1.6D							IC50 (μg/mL): DENV1: 1.5 DENV2: 0.2 DENV3: 0.5 DENV4: 2.7

2H12	Murine	DENV1–4	E	DIII (AB loop: aa 314–317)	Hybridoma from BALB/c mouse immunized with DENV2 E/DIII	IgG2b	IC50 nM: DENV1: 0.56–54 DENV3: 29 DENV4: 145	[38]

C9	Murine/chimeric	DENV2	E	DIII	Phage display of a chimeric murine hybridoma library	VH1/Vκ1	PRNT50 850 μg/mL	[39]

4E11	Murine	DENV1–4	E	DIII (strand A: 308, 312 and strand G: 387, 389, 391)	Hybridoma	IgG2a/κ	IC50 (μg/mL): DENV10.16 DENV2: 0.13 DENV-3: 8 DENV-4: 15	[40]

4G2	Murine	DENV1–4	E	DII (fusion loop)	Hybridoma from DENV2 E immunized mice	IgG	PRNT50 (μg/mL): DENV2: 15	[39]

9F12	Murine	DENV1–4, WNV	E	DIII (aa 305, 307, 310, 330; A strand and BC loop)	Hybridoma from BALB/c mouse immunized with DENV-2 E/DIII	IgG1k	DENV1–4PRNT50: – M	[41]

2A10G6	Murine	DENV1–4, YFV, WNV, JEV, TBEV	E	DII (Fusion loop: aa 98–101)	Hybridoma from BALB/c mouse immunized with inactivated DENV2	IgG1	PRNT50 (μg/mL): DENV1: 2 DENV2: 1.5 DENV3: 2.1 DENV4: 1.8 YNF: 3.6 WNV: 46	[36]

mAb11	Human	DENV1–4, WNV, SLEV, YFV, JEV MVEV	E	DII (fusion loop)	Phage display of human scFv	Fusion protein scFv-Fc	PRNT80 (μg/mL): WNV: 1.25 DENV2: 6.25	[42, 43]

E16 (MGAWN1)	Murine	WNV	E	DIII (LR; aa 302–309)	Hybridoma from immunized mice with WNV E	IgG2b/humanized	PRNT50: 4–18 ng PRNT90: 53–297 ng	[44, 45]

1A1D-2	Murine	DENV1–3	E	DIII (A strand: aa 307, 310 and 312)	Hybridoma from immunized mice with different pH-treated virus	IgG2a	DENV2 PRNT50: 2.1 nM	[46, 47]

1F4	Human	DENV1	E (virion)	DI-DII	Electrofusion of infected memory B cells from DENV-immune subjects with EBV	IgG	DENV1 IC50 0.11 μg/mL	[48]
2D22		DENV2		DIII			DENV2 IC50 0.08 μg/mL
5J7		DENV3		DI-DII			DENV3 IC50 0.10 μg/mL

E105	Murine	DENV1	E	DIII (BC loop: G328, T329 and D330; DE loop: K361E and E362K; FG loop: K385)	Hybridomas derived from C57BL/6 IFN-α βR^−/− mice infected with DENV1	IgG	PRNT50 DENV-1: 0.5–59.2 ng/mL	[32]
E106				DIII (BC loop: G328, T329 and D330; DE loop: K361E and E362K; FG loop: K385; A strand: S305, K307, E309, K310, and E311)			PRNT50 DENV-1: 0.6–59.2 ng/mL	[32]
E111				DIII (CC′ loop)			PRNT50: 3.8–25 μg/mL	[49]

CR4374	Human	WNV	E	DIII	Phage display of scFv IgG library	VH2-05/VL1e	PRNT50: 0.18 μg/mL PRNT90: 0.95 μg/mL	[50]
CR4353	Human	WNV	E	DIII	Phage display of scFv IgG library	VH3-30/Vk3-A27	PRNT50: 0.026 μg/mL PRNT90 36.4 μg/mL	[50]

1A5	Chimpanzee	DENV1–4, WNV, JEV, LGTV	E	DII (aa G106)	Phage display of Fab library from DENV1–4 infected chimpanzees	Humanized IgG1	PRNT50 (μg/mL): DENV1: 0.48 DENV2: 0.95 DENV3: 3.2 DENV4: 4.3 WNV/DENV4: 3.8 JEV: 21 LGTV: 28	[51]

mAb11	Human	DENV1–4, WNV	E	DII (fusion loop, W101, G104, G106)	scFv library	scFv-Fc	PRNT80 (μg/mL): DENV2: 6.25 WNV: 1.25	[42, 43]

3B4C-4	Murine	SLEV	E	1a	Hybridoma	IgG	SLEV PRNT: <1.7	[52, 53]
1B2C-5		SLEV		1b			SLEV PRNT: <1.7
6B5A-2		SLEV		1c			SLEV PRNT: 4.8
4A4C-4		SLEV		1d			SLEV PRNT: 2.9
1B5D-1		SLEV, JEV		2			SLEV PRNT: <1.7
2B5B-3		SLEV, JEV, MVEV, WNV, YFV		3			SLEV PRNT: 2.3
2B6B-2		All Flavivirus		4a			SLEV PRNT: <1.7
6B6C-1		All Flavivirus		4b (in DII)			SLEV PRNT: 2.3

A3	Chimpanzee	JEV	E2	DI aa. K179	Phage display	Humanized	PRNT50 0.04–0.2 nM	[54]
B2				DII aa. I126	Phage display		PRNT50 0.02–2 nM
E3				DIII aa. G132	Phage display		PRNT50 0.14–0.93 nM

FabTJE12B02	Human	JEV	E	N/A	Phage display	Fab	FRNT50 50.2 µg/mL	[55]

5F10	Human	CHIKV	E2	Domain B	EBV transformation	IgG1λ2	IC50 < 100 ng/mL	[56]
8B10	Human	CHIKV	E1-E2	E2 Domain A	EBV transformation	IgG1k	IC50 < 100 ng/mL	[56]

CHK-152	Murine	CHIKV	E2	aa 59	Hybridoma	IgG2c	IC50 1–3 ng/mL	[57]

11E7	Murine	CCHFV	Gn	C-ter	Hybridoma	IgG	PRNT80 diluted 1/2560	[58]

4-39-CC	Murine	RVFV	G2	Domain IV	Hybridoma	IgG	PRNT80 diluted 1/20480–1/81920	[59]

2C9	Murine	YFV	E		Hybridoma	IgG2a	PRNT90: 1/10⁴ 17D 1/10^5.2 Asibi	[60]

5A 7A R3(27)	Human	YFV	E	DI-DII	Phage display	ScFv	PRNT90: 0.1–0.3 μg/mL	[61]

13D6	Murine	TBEV	E	DIII	Hybridoma	IgG/chimeric	PRNT50: 1.9 μg/mL FRNT50: 4.5 μg/mL IC50 1.9–16.7 μg/mL	[62]

3B4C-4 (Hy4-26C)	Murine	VEEV	E2	aa 182–209	Hybridoma	IgG/humanized	PRNT70 (μg/mL): 39.4–125	[63]